VLP-based vaccine developers

VLP Therapeutics is a clinical-stage biotechnology company specializing in the development of next-generation vaccines using proprietary virus-like particle (VLP) and self-amplifying RNA (saRNA) technologies. The company's platform aims to enhance the immune response while reducing the required dosage and potential side effects compared to traditional vaccine methods. Their lead programs include a COVID-19 booster vaccine and a highly anticipated malaria vaccine candidate. Beyond infectious diseases, VLP Therapeutics is leveraging its platform to develop therapeutic vaccines for cancer and neurodegenerative disorders like Alzheimer's disease. Headquartered in Maryland with a significant presence in Japan, the company collaborates extensively with academic and governmental institutions to address global health challenges.